Our results may support combinatory immunotherapeutic strategies, especially for targeting anti-PD-1 and/or anti-LAG-3 with anti-CD163 or macrophage inhibitors in advanced cutaneous melanoma. The gene discussed is CD163; the disease is cutaneous melanoma.